12/4
10:20 pm
engn
enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial [Yahoo! Finance]
Medium
Report
enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial [Yahoo! Finance]
12/3
08:44 am
engn
enGene (NASDAQ:ENGN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
enGene (NASDAQ:ENGN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/2
07:30 am
engn
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
Low
Report
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
11/25
07:30 am
engn
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
11/13
12:27 am
engn
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
Medium
Report
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
11/12
04:01 pm
engn
enGene Announces Proposed Public Offering of Common Shares
Low
Report
enGene Announces Proposed Public Offering of Common Shares
11/12
12:22 pm
engn
enGene (NASDAQ:ENGN) had its price target raised by analysts at Morgan Stanley from $18.00 to $19.00. They now have an "overweight" rating on the stock.
Medium
Report
enGene (NASDAQ:ENGN) had its price target raised by analysts at Morgan Stanley from $18.00 to $19.00. They now have an "overweight" rating on the stock.
11/12
09:37 am
engn
enGene (NASDAQ:ENGN) had its price target raised by analysts at Citizens Jmp from $18.00 to $21.00. They now have a "market outperform" rating on the stock.
Medium
Report
enGene (NASDAQ:ENGN) had its price target raised by analysts at Citizens Jmp from $18.00 to $21.00. They now have a "market outperform" rating on the stock.
11/12
09:07 am
engn
enGene (NASDAQ:ENGN) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
enGene (NASDAQ:ENGN) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
11/12
08:05 am
engn
enGene (NASDAQ:ENGN) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
enGene (NASDAQ:ENGN) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/12
08:05 am
engn
enGene (NASDAQ:ENGN) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
Low
Report
enGene (NASDAQ:ENGN) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
11/11
10:10 am
engn
enGene (NASDAQ:ENGN) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating. They now have a $27.00 price target on the stock.
High
Report
enGene (NASDAQ:ENGN) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating. They now have a $27.00 price target on the stock.
11/11
07:30 am
engn
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
High
Report
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
11/10
04:05 pm
engn
enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
High
Report
enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
11/6
05:00 pm
engn
enGene to Participate in Upcoming Investor Conferences
Low
Report
enGene to Participate in Upcoming Investor Conferences
11/4
01:35 pm
engn
enGene Named a BioSpace 2026 Best Places to Work Winner
Medium
Report
enGene Named a BioSpace 2026 Best Places to Work Winner
10/14
12:13 pm
engn
enGene (NASDAQ:ENGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
enGene (NASDAQ:ENGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/3
03:35 pm
engn
enGene (NASDAQ:ENGN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
enGene (NASDAQ:ENGN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/1
04:03 pm
engn
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9/30
07:30 am
engn
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
Medium
Report
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
9/12
12:17 pm
engn
enGene (NASDAQ:ENGN) had its price target lowered by analysts at Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.
Medium
Report
enGene (NASDAQ:ENGN) had its price target lowered by analysts at Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.
9/11
04:03 pm
engn
enGene Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
enGene Reports Third Quarter 2025 Financial Results and Provides Business Update
9/8
08:05 am
engn
enGene (NASDAQ:ENGN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
enGene (NASDAQ:ENGN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.